Center for Transport Oncophysics

拟议的运输肿瘤物理中心(CTO)是五个机构之间的合作计划。 首席调查员是毛罗·费拉里博士(UTHSC-H)，高级联合调查员是史蒂文博士 库里(MDACC)。因此，拟议的首席技术官的第一个总体具体目标是构建一个 系统“，其中多维的”单位向量“是微分定律 通过一组基本的生物屏障传输物理，因为它们呈现自己并在 肿瘤发生学(即“运输物理学”)。第二个最重要的具体目标是演示 CTO内开发的新系统和方法的疗效(多阶段系统， 纳米穿梭、碳纳米管、金胶体、口服给药载体)。 拟议的CTO将具有以下特点：1.单一的科学框架(以运输和物理为区别， 和生物屏障作为运输节点)；2.综合的“多多尺度”方法(我们的 数学、工程探测器和成像仪器都是多尺度的，在这里被用来 研究生物壁垒的多尺度架构)反映在共享核心和所有项目平台中 可作为其他项目的核心；3.“双重意图”的运作方式， 用于基本发现的工程运输探测器也被用于演示 针对两个癌症聚集区未解决的临床需求的创新治疗方式；4. 癌症病灶和动物模型的综合选择。第一个聚集性病灶是肝癌，包括原发性和 转移性(项目1-3)，第二是结直肠癌(项目4-5)，有令人信服的联系是 结直肠癌肝转移方面动物模型的选择 在费德勒博士的指导下，重述人类疾病。进一步调查，解决 运输方面的补充和协同作用将在整个行动中展开 通过试点项目机制对首席技术官进行培训。

The proposed Center for Transport OncoPhysics (CTO) is a collaborative program among five institutions. The Principal Investigator is Dr. Mauro Ferrari (UTHSC-H) and the Senior Co-Investigator is Dr. Steven Curiey (MDACC). Thus, the first overall specific aim of the proposed CTO is to construct a "reference system" for the understanding of cancer, where the multi-dimensional "unit vectors" are the differential laws of transport physics across a fundamental set of biobarriers as they present themselves and evolve in tumorogenesis (i.e., "transport oncophysics"). The second overarching Specific Aim is to demonstrate the therapeutic efficacy of the novel systems and approaches developed within the CTO (multi-stage systems, nanoshuttles, carbon nanotubes, gold colloids, oral administration carriers) in the respective animal models. The proposed CTO will feature: 1. A single scientific framework ("transport oncophysics" as the differential, and biological barriers as the transport nodes); 2. An integrated "multiple multi-scale" approach (our mathematics, engineered probes, and imaging instrumentation are all multiscale, and are here employed to study the multiscale architecture of the biological barriers) reflected in shared cores and all project platforms being available to serve as cores for other projects; 3. A "dual-intent" operational approach, with the engineered transport probes used for basic discovery also being employed forthe demonstration of innovative therapeutic modalities addressing unsolved clinical needs in two cancer focus cluster areas; 4. An integrated choice of cancer focus and animal models. The first focus cluster is liver cancer, both primary and metastatic (Projects 1-3), the second is colorectal cancer (Projects 4-5), with cogent connections being the liver metastasis aspect of colorectal cancer, and the choice of unified animal models that sincerely recapitulate human diseases, under the guidance of Dr. Fidler. Further investigations that address complementary and synergistic aspects of transport onco-physics will be launched throughout the operations of the CTO by means of the Pilot Projects mechanism.